Clinical Report: Managing DME When Anti-VEGF Response Is Limited
Overview
The ERYLDEX study indicates that switching to dexamethasone intravitreal implant (DEX-I) after inadequate anti-VEGF response can significantly improve visual acuity and reduce central subfield thickness in patients with diabetic macular edema (DME). This approach may prevent further vision loss compared to continued anti-VEGF therapy.
Background
Diabetic macular edema (DME) is a common complication of diabetes that can lead to vision impairment. Anti-VEGF therapy is the first-line treatment; however, a significant proportion of patients experience suboptimal responses. Understanding alternative treatment options is crucial for optimizing patient outcomes and preventing vision loss.
Data Highlights
Outcome
DEX-I Group
Anti-VEGF Group
Vision Gain (letters)
~8 letters
No gain
CST Improvement (µm)
~120 µm
Modest decrease
Patients Gaining 10 Letters
50%
6%
Patients Gaining 15 Letters
25%
4%
Patients Losing 10+ Letters
0%
10%
Patients Losing 15+ Letters
0%
8.5%
Key Findings
Switching to DEX-I after inadequate anti-VEGF response resulted in an average vision gain of 8 letters.
Patients switched to DEX-I showed a significant improvement in central subfield thickness (CST) by 120 µm at week 12.
50% of patients switched to DEX-I gained 10 letters compared to only 6% on anti-VEGF therapy.
No patients in the DEX-I group lost 10 or more letters, while 10% of those on anti-VEGF did.
Early switching to DEX-I is recommended after 3 injections of anti-VEGF for better outcomes.
Clinical Implications
Clinicians should consider switching patients with DME to dexamethasone implants after 3 to 6 anti-VEGF injections if there is a suboptimal response. This strategy may enhance visual outcomes and reduce the risk of vision loss, emphasizing the need for regular monitoring of CST and visual acuity.
Conclusion
The findings from the ERYLDEX study support the early transition to dexamethasone implants in patients with inadequate responses to anti-VEGF therapy, potentially improving patient outcomes in managing diabetic macular edema.
